Verified peer comparison

AMGN vs GILD

Amgen Inc. compared with Gilead Sciences, Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

AMGN

Amgen Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

GILD

Gilead Sciences, Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

AMGN: Biotechnology

GILD: Biotechnology

Upside lens

AMGN: Broad volume growth across Repatha, EVENITY, rare-disease and oncology products can offset declines in mature brands. MariTide and other Phase 3 programs can create new growth franchises if clinical and regulatory milestones succeed. Expansion of UPLIZNA, IMDELLTRA and other newer medicines can diversify product growth.

GILD: Biktarvy leadership and Yeztugo adoption can sustain treatment and prevention growth. Trodelvy demand and acquired cell-therapy and antibody-drug-conjugate assets can diversify the portfolio. Livdelzi uptake can add a new growth leg alongside established antiviral franchises.

Risk lens

AMGN: Competition is accelerating declines in Prolia, XGEVA and other established products. Medicare price setting, 340B mix, payer pressure and global reforms can reduce net selling prices. Clinical failures can impair growth expectations while acquisition-related debt and commitments limit flexibility.

GILD: Heavy reliance on HIV leaves earnings exposed to competition, payer pressure and patent transitions. Large acquisitions and acquired research charges can consume capital without producing approved products. Manufacturing complexity and intense competition can pressure patient access and cell-therapy sales.